| 2025年中报 | 2024年年报 | 2024年中报 | 2023年年报 | 2023年中报 | |
|---|---|---|---|---|---|
| 营业收入(元) | |||||
| 生物制药报告分部(元) | 104,178,683.83 | - | 78,351,402.74 | - | 78,362,920.69 |
| 体外诊断试剂分部(元) | 1,934,682.27 | - | 2,718,511.27 | - | 2,004,996.74 |
| 医药技术服务报告分部(元) | 142,542,600.49 | - | 186,748,564.57 | - | 179,715,029.14 |
| 原料药及医药中间体(元) | 26,102,751.22 | - | 16,549,575.26 | - | 23,308,194.36 |
| 技术服务收入(元) | - | 411,166,272.17 | - | 368,573,003.35 | - |
| 注射用鼠神经生长因子(金路捷)(元) | - | 120,845,378.96 | - | 132,722,293.47 | - |
| 注射用埃普奈明(元) | - | 26,368,276.45 | - | - | - |
| 其他(元) | 305,060.34 | 90,594,196.40 | 256,500.95 | 100,989,010.09 | 116,784.60 |
| 营业成本(元) | |||||
| 生物制药报告分部(元) | - | - | - | - | - |
| 体外诊断试剂分部(元) | - | - | - | - | - |
| 医药技术服务报告分部(元) | - | - | - | - | - |
| 原料药及医药中间体(元) | - | - | - | - | - |
| 技术服务收入(元) | - | 227,833,857.61 | - | 211,484,456.77 | - |
| 注射用鼠神经生长因子(金路捷)(元) | - | 24,189,365.79 | - | 23,776,808.01 | - |
| 注射用埃普奈明(元) | - | - | - | - | - |
| 其他(元) | - | - | - | 109,793,788.24 | - |
| 毛利(元) | |||||
| 生物制药报告分部(元) | - | - | - | - | - |
| 体外诊断试剂分部(元) | - | - | - | - | - |
| 医药技术服务报告分部(元) | - | - | - | - | - |
| 原料药及医药中间体(元) | - | - | - | - | - |
| 技术服务收入(元) | - | 183,332,414.56 | - | 157,088,546.58 | - |
| 注射用鼠神经生长因子(金路捷)(元) | - | 96,656,013.17 | - | 108,945,485.46 | - |
| 注射用埃普奈明(元) | - | - | - | - | - |
| 其他(元) | - | - | - | -8,804,778.15 | - |
| 毛利率(%) | |||||
| 生物制药报告分部(%) | - | - | - | - | - |
| 体外诊断试剂分部(%) | - | - | - | - | - |
| 医药技术服务报告分部(%) | - | - | - | - | - |
| 原料药及医药中间体(%) | - | - | - | - | - |
| 技术服务收入(%) | - | 44.59 | - | 42.62 | - |
| 注射用鼠神经生长因子(金路捷)(%) | - | 79.98 | - | 82.09 | - |
| 注射用埃普奈明(%) | - | - | - | - | - |
| 其他(%) | - | - | - | -8.72 | - |
| 收入构成(%) | |||||
| 生物制药报告分部(%) | 37.87 | - | 27.53 | - | 27.64 |
| 体外诊断试剂分部(%) | 0.70 | - | 0.96 | - | 0.71 |
| 医药技术服务报告分部(%) | 51.82 | - | 65.61 | - | 63.39 |
| 原料药及医药中间体(%) | 9.49 | - | 5.81 | - | 8.22 |
| 技术服务收入(%) | - | 63.36 | - | 61.20 | - |
| 注射用鼠神经生长因子(金路捷)(%) | - | 18.62 | - | 22.04 | - |
| 注射用埃普奈明(%) | - | 4.06 | - | - | - |
| 其他(%) | 0.11 | 13.96 | 0.09 | 16.77 | 0.04 |
| 毛利构成(%) | |||||
| 生物制药报告分部(%) | - | - | - | - | - |
| 体外诊断试剂分部(%) | - | - | - | - | - |
| 医药技术服务报告分部(%) | - | - | - | - | - |
| 原料药及医药中间体(%) | - | - | - | - | - |
| 技术服务收入(%) | - | 65.48 | - | 61.07 | - |
| 注射用鼠神经生长因子(金路捷)(%) | - | 34.52 | - | 42.35 | - |
| 注射用埃普奈明(%) | - | 0.00 | - | - | - |
| 其他(%) | - | 0.00 | - | -3.42 | - |